Fecal transplant for lymphoma patients getting CAR T therapy
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether giving a fecal transplant (a stool enema from a healthy donor) can improve the response to CAR T-cell therapy in people with B-cell lymphoma. It may help by restoring healthy gut bacteria that are often wiped out by strong antibiotics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have B-cell lymphoma (a type of blood cancer).
- You are scheduled to receive a CAR T-cell therapy called axicabtagene ciloleucel (YesCAR T).
- You have received strong antibiotics for at least 2 days in the past 6 months (like meropenem, cefepime, or metronidazole).
- You are in fairly good health (able to care for yourself, up and about more than half the day).
- Your liver and kidneys are working well enough, and your blood counts are stable enough for a fecal enema.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a fecal transplant (transferring healthy gut bacteria) can improve outcomes for people with certain lymphomas who have taken strong antibiotics and are about to get CAR T-cell therapy (Yescarta). The goal is to see if rebuilding gut bacteria helps the treatment work better.
This pilot study tests whether giving a fecal microbiota transplant before standard CAR-T therapy (for B-cell lymphoma) or reduced-intensity stem cell transplant (for AML or high-risk MDS) can improve treatment outcomes. It aims to see if restoring gut bacteria helps reduce complications.
This trial tests whether a fecal microbiota transplant (FMT) — transferring healthy bacteria from a donor's stool into your gut — combined with the immunotherapy drug tislelizumab can help treat advanced non-small cell lung cancer (NSCLC) that has progressed after prior treatments. It aims to see if this combination can improve outcomes by boosting your immune system's response.
This trial tests whether a special mix of gut bacteria can make CAR-T cell therapy work better for people with large B-cell lymphoma or multiple myeloma. You will take capsules of these bacteria before and during CAR-T treatment to see if it helps your body respond to the therapy.
This trial tests whether taking an oral fecal transplant (MaaT033) along with the immunotherapy drug cemiplimab can help people whose lung cancer stopped responding after antibiotics. It's for people with advanced non-small cell lung cancer whose cancer got worse after standard immunotherapy.
This trial studies whether giving a fecal microbiota transplant (a stool-based sample from a carefully screened donor) alongside immune checkpoint inhibitors can improve outcomes in people with lung cancer. It aims to change the gut bacteria to help the immune system work better against the cancer.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.